跳过内容

有氧运动Update

人造心脏:需要较小心脏,目的地治疗的人的更多选择

118金宝搏抽水宾夕法尼亚州健康米尔顿·S·赫尔希医疗中心已经加入了两项评估人造心脏(TAH)的多中心试验,并可以挽救更多不可逆的双室心力衰竭患者的生命(BVHF)。观察性研究的重点是伴侣症®根据对81例患者的研究,TAH首先被FDA批准为70cc大小的移植桥,其中79%幸存下来接受移植。1

Image of SynCardia® TAHThe first study examines the safety of the 70cc device for use as destination therapy in patients with life-threatening BVHF who are ineligible for cardiac transplant. To date, 12 centers, including Milton S. Hershey Medical Center, are set to enroll patients and follow them for six months to confirm the device’s benefits. Researchers define success as survival to six months without permanent deficits from stroke. Patients may also participate in a secondary arm of the trial to determine whether a broader patient population would also benefit from the device.2

第二项研究评估了一个新的Syncardia 50cc TAH,作为10至75岁的小儿科患者的移植桥梁,他们有即将死亡的风险并且有资格接受供体的心脏。2015年,心脏和血管研究所是美国第一个接收50cc syncardia tah设备作为国家试验的一部分。它是该设备的较小版本,可用于太小的患者,无法从标准的70cc设备中受益。主要结果是生存,而次要安全相关的结果包括中风率降低,慢性肾脏感染,装置故障和主要感染。3

2007年,米尔顿·赫尔希医学中心(Milton S. Hershey Medical Center)成为宾夕法尼亚州中部第一家植入Syncardia tah的医院。此后,好时医学中心已经植入了15个设备,仅在2015年就进行了7次手术,仅进行了7台设备。Behzad Soleimani, MD,移植和机械循环支持手术主管。这些数字使该研究所的Syncardia Tah植入手术量成为2015年提供植入程序的64个中心中的第二高。

好时医学中心(Hershey Medical Center)拥有新的人工心脏技术的悠久历史,可以追溯到1985年,当时医院植入了第一台(TAH),这是一种空中驱动设备。1993年,它是从国家心脏,肺部和血液研究所获得三年,540万美元的合同,以继续开发完全可植入的电动心脏的工作。

朝着这个目标研究关注transcutaneous transfer technology that would eliminate the drive-line that connects current TAH devices to external power sources and address hemocompatibility issues, which previously led to high rates of stroke in patients who received totally implantable electric hearts, says Dr. Soleimani. “We are still looking for a totally implantable artificial heart that is both hemocompatible and has no drive-line. That is the holy grail,” he adds.

贝扎德·索利马尼(Behzad Soleimani),医学博士

Behzad Soleimani, MD

(临时),宾夕法尼亚州立心脏和血管研究所
心脏手术部门首席
Surgical Director, Heart Transplantation and Mechanical Circulatory Support
副教授
电话:717-531-8330
电子邮件:bsoleimani@pennstatehealth.psu.edu
奖学金:NHS基金会信托基金会Harefield医院的心肺移植手术,英格兰Middlesex
居住:心胸外科手术和普通外科,英格兰皇家外科医生,英格兰伦敦
医学院:剑桥大学医学院,英格兰剑桥
与医学博士Behzad Soleimani连接

参考:

  1. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH T, McClellan D, Slepian MJ; CardioWest Total Artificial Heart Investigators.心脏替换为完全人造心脏作为移植的桥梁N Engl J Med2004; 351:859-867.
  2. https://clinicaltrials.gov/ct2/show/nct02232659?term = syncardia+70++cc+cc+tah+as+destation+destination+therapy&rank = 1。2016年2月12日访问。
  3. https://pennstatehersheycardioreport.org/2016/01/08/non-sternotomy-valve-surgery-eases-cardiac-recovery-for-patients/。2016年2月12日访问。

宾夕法尼亚州立心脏和血管研究所(PSHVI)是全国心脏和血管护理,研究和医学教育的国家模型。胸外科医生协会将PSHVI评为全美最精英计划,并获得了三星级评级。我们是宾夕法尼亚州中部唯一的心脏移植中心,包括人造心脏位置。

World-renowned doctors, skilled physician extenders, and Magnet-recognized nurses work together to provide advanced care for both common and complex heart and vascular conditions. PSHVI provides options for treating structural heart disease, including TVAR, Watchman and MitraClip, and delivers Joint Commission-accredited programs in advanced heart failure and implanting ventricular assist devices as a long-term treatment or as a bridge to heart transplant.

Our PSHVI physicians and scientists are committed to advancing the knowledge of causes and effects of cardiovascular disease through research and clinical trials and to training the physicians of the future.

推荐病人


继续教育活动

View Programs


请了解所有感兴趣的继续教育活动。

今天订阅

Baidu